Literature DB >> 29860251

The Efficacy of a Group CBT Relapse Prevention Program for Remitted Anxiety Disorder Patients Who Discontinue Antidepressant Medication: A Randomized Controlled Trial.

Willemijn D Scholten1,2, Neeltje M Batelaan1,2, Patricia van Oppen1,2, Johannes H Smit1,2, Adriaan W Hoogendoorn1,2, Harold J G M van Megen3, Daniëlle C Cath4,5,6,7, Anton J L M van Balkom1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29860251      PMCID： PMC6492611          DOI： 10.1159/000489498

Source DB:  PubMed          Journal:  Psychother Psychosom        ISSN： 0033-3190            Impact factor:   17.659


× No keyword cloud information.
  9 in total

1.  Withdrawal Symptoms after Selective Serotonin Reuptake Inhibitor Discontinuation: A Systematic Review.

Authors:  Giovanni A Fava; Alessia Gatti; Carlotta Belaise; Jenny Guidi; Emanuela Offidani
Journal:  Psychother Psychosom       Date:  2015-02-21       Impact factor: 17.659

2.  New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal.

Authors:  Guy Chouinard; Virginie-Anne Chouinard
Journal:  Psychother Psychosom       Date:  2015-02-21       Impact factor: 17.659

3.  Persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy.

Authors:  Carlotta Belaise; Alessia Gatti; Virginie-Anne Chouinard; Guy Chouinard
Journal:  Psychother Psychosom       Date:  2014-06-19       Impact factor: 17.659

4.  Rational use of antidepressant drugs.

Authors:  Giovanni A Fava
Journal:  Psychother Psychosom       Date:  2014-06-19       Impact factor: 17.659

Review 5.  The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis.

Authors:  Jacob Piet; Esben Hougaard
Journal:  Clin Psychol Rev       Date:  2011-05-15

6.  Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology.

Authors:  David S Baldwin; Ian M Anderson; David J Nutt; Christer Allgulander; Borwin Bandelow; Johan A den Boer; David M Christmas; Simon Davies; Naomi Fineberg; Nicky Lidbetter; Andrea Malizia; Paul McCrone; Daniel Nabarro; Catherine O'Neill; Jan Scott; Nic van der Wee; Hans-Ulrich Wittchen
Journal:  J Psychopharmacol       Date:  2014-04-08       Impact factor: 4.153

7.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.

Authors:  Borwin Bandelow; Joseph Zohar; Eric Hollander; Siegfried Kasper; Hans-Jürgen Möller; Joseph Zohar; Eric Hollander; Siegfried Kasper; Hans-Jürgen Möller; Borwin Bandelow; Christer Allgulander; José Ayuso-Gutierrez; David S Baldwin; Robertas Buenvicius; Giovanni Cassano; Naomi Fineberg; Loes Gabriels; Ian Hindmarch; Hisanobu Kaiya; Donald F Klein; Malcolm Lader; Yves Lecrubier; Jean-Pierre Lépine; Michael R Liebowitz; Juan José Lopez-Ibor; Donatella Marazziti; Euripedes C Miguel; Kang Seob Oh; Maurice Preter; Rainer Rupprecht; Mitsumoto Sato; Vladan Starcevic; Dan J Stein; Michael van Ameringen; Johann Vega
Journal:  World J Biol Psychiatry       Date:  2008       Impact factor: 4.132

8.  Discontinuation of antidepressant medication after mindfulness-based cognitive therapy for recurrent depression: randomised controlled non-inferiority trial.

Authors:  Marloes J Huijbers; Philip Spinhoven; Jan Spijker; Henricus G Ruhé; Digna J F van Schaik; Patricia van Oppen; Willem A Nolen; Johan Ormel; Willem Kuyken; Gert Jan van der Wilt; Marc B J Blom; Aart H Schene; A Rogier; T Donders; Anne E M Speckens
Journal:  Br J Psychiatry       Date:  2016-02-18       Impact factor: 9.319

Review 9.  Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials.

Authors:  Neeltje M Batelaan; Renske C Bosman; Anna Muntingh; Willemijn D Scholten; Klaas M Huijbregts; Anton J L M van Balkom
Journal:  BMJ       Date:  2017-09-13
  9 in total
  6 in total

1.  Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.

Authors:  Ellen Van Leeuwen; Mieke L van Driel; Mark A Horowitz; Tony Kendrick; Maria Donald; An Im De Sutter; Lindsay Robertson; Thierry Christiaens
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

Review 2.  Barriers to discontinuing antidepressants in patients with depressive and anxiety disorders: a review of the literature and clinical recommendations.

Authors:  Willemijn Scholten; Neeltje Batelaan; Anton Van Balkom
Journal:  Ther Adv Psychopharmacol       Date:  2020-06-10

3.  Patients' attitudes to discontinuing not-indicated long-term antidepressant use: barriers and facilitators.

Authors:  Rhona Eveleigh; Anne Speckens; Chris van Weel; Richard Oude Voshaar; Peter Lucassen
Journal:  Ther Adv Psychopharmacol       Date:  2019-09-03

4.  Psychological interventions to prevent relapse in anxiety and depression: A systematic review and meta-analysis.

Authors:  Esther Krijnen-de Bruin; Willemijn Scholten; Anna Muntingh; Otto Maarsingh; Berno van Meijel; Annemieke van Straten; Neeltje Batelaan
Journal:  PLoS One       Date:  2022-08-12       Impact factor: 3.752

5.  Discontinuing antidepressant medication after mindfulness-based cognitive therapy: a mixed-methods study exploring predictors and outcomes of different discontinuation trajectories, and its facilitators and barriers.

Authors:  Marloes J Huijbers; Carolien Wentink; Esther Simons; Jan Spijker; Anne Speckens
Journal:  BMJ Open       Date:  2020-11-11       Impact factor: 2.692

6.  To continue or discontinue antidepressants in anxiety disorders? A dilemma for patients and clinicians.

Authors:  Anna Muntingh; Neeltje Batelaan; Willemijn Scholten; Anton J van Balkom
Journal:  J Psychiatry Neurosci       Date:  2021-06-02       Impact factor: 6.186
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.